EV/EBITDA Multiple: Aardvark Therapeutics Corp (AARD)

Corporate company logo of aardvarktherapeutics.com (AARD)

Aardvark Therapeutics Inc (AARD) is developing cutting-edge treatments for metabolic disorders, leveraging a substantial amount of liquid assets and protected intellectual property. Serving as the primary valuation tool, this chart on GURU.Markets captures the 0.00 metric. However, global instability and trade restrictions are hindering the conduct of cross-border trials, significantly complicating the worldwide implementation of new medical products.

AARD (Aardvark Therapeutics Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/16/2026

Aardvark Therapeutics Inc. (AARD) - metric breakdowns and financial figures

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Initial company analysis:AARD (Aardvark Therapeutics Inc)
Product sample of Aardvark Therapeutics

The fundamental attractiveness of Aardvark Therapeutics Inc (AARD) is determined by the ratio of total enterprise value to its operating profit before depreciation and amortization. The current EV/EBITDA multiple valuation allows for the identification of hidden asset degradation by comparing market capitalization with actual cash flow. This indicator is critical for Aardvark Therapeutics Inc (AARD), as the outsourcing of small molecule production impacts the cost structure. Low metric values signal undervaluation, while extreme peaks indicate a risk of capital freeze.

Who Aardvark Therapeutics Inc competes with

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ascendispharma.com ASND|MDGL - Enterprise Value to EBITDA Ratio|Corcept Therapeutics Corp - EV/EBITDA Multiple|Company Value to EBITDA Rhythm Pharmaceuticals Inc|AKRO (Akero) - Enterprise Value to EBITDA Ratio|MTSR: Enterprise Value to Operating Income Before Depreciation Ratio|MLTX (MoonLake Corp) - EV/EBITDA Multiple|EV/EBITDA Multiple Crinetics Pharmaceuticals|EV/EBITDA Multiple NAMS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SLNO (Soleno Therapeutics Inc)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization amicusrx.com FOLD|89bio Pharma (ETNB) - Company Value to EBITDA|AGIO - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GPCR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MDXG: EV/EBITDA Multiple|RZLT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexicon Corp|Enterprise Value to EBITDA Ratio MBX Corp (MBX)|EV/EBITDA Multiple ALT|Enterprise Value to EBITDA Ratio sagimet.com SGMT|EV/EBITDA Multiple BIOA (BioAge)|Biomea Fusion - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|QNCX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Enterprise Value to EBITDA Ratio|Agape ATP Corp. (ATPC) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization pluri-biotech.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SYBX|EV/EBITDA Multiple LPCN|Matinas BioPharma Holdings - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple SPRB (sprucebiosciences.com)|Enterprise Value to Operating Income Before Depreciation Ratio GLTO (galecto.com)|CTCX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio LUMO|organovo.com (ONVO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Radius Health - Business Value to Operating Income Before Depreciation